Frazier Life Sciences Management L.P. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 885,165 shares of the company’s stock after acquiring an additional 271,122 shares during the […]
KPP Advisory Services LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,196 shares of the company’s stock after buying an additional 1,675 shares during the quarter. KPP […]
Rhenman & Partners Asset Management AB lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 53.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 100,400 shares of the company’s stock after selling 114,600 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Apellis Pharmaceuticals were […]
HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Wedbush from $67.00 to $57.00 in a report issued on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 […]